secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-09-16T20:05:40+00:00
Accession:  0001728117-26-000101
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio appoints Greg Ciongoli to board, Audit Committee
-------------------------------------------------------------

- Ciongoli, Class III director effective Sept 16, 2026, term to 2027 annual meeting; joins Audit Committee.
- Founder/managing partner of Adiumentum Capital (since 2024); ex-Baupost Group partner; also on REGENXBIO, Zymeworks, Atara boards.
- He participated in Aug 2026 PIPE: pre-funded warrants for ~22,337 common (initial), ~111,687 (second closing), ~66,845 (FDA approval) post-approval.
- Annual cash retainers: $40,000 board, $7,500 audit; standard equity award amount set at future board discretion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/0001728117-26-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000101/goss-20260916.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer